Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: A prospective, open-label, multi-center trial

Vaccine

Volumn 28, Issue 36, 2010, Pages 5857-5863

  Oh, Chi Eun ^a,b   Lee, Jina ^a   Kang, Jin Han ^c   Hong, Young Jin ^d   Kim, Yun Kyung ^e   Cheong, Hee Jin ^e   Ahn, Young Joo ^f   Kim, Sang Hoon ^f   Lee, Hoan Jong ^a,g  

^a Seoul National University Children's Hospital   (South Korea)

^b Kosin University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e Korea University College of Medicine   (South Korea)

^f Green Cross Company   (South Korea)

^g Seoul National University College of Medicine   (South Korea)

Author keywords

H1N1 virus; Influenza vaccine; Pandemic

Indexed keywords

ANTIGEN; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADOLESCENT; ADULT; APPETITE DISORDER; ARTHRALGIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHILD; CLINICAL TRIAL; COMMON COLD; COUGHING; CRYING; DIARRHEA; DROWSINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFANT; INFLUENZA A (H1N1); IRRITABILITY; KOREA; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MYALGIA; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SHIVERING; SIDE EFFECT; SWEATING; SWELLING; VIRUS INACTIVATION;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; VACCINES, INACTIVATED;

EID: 77955554467     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.060     Document Type: Article

References (30)

1. World Health Organization. Pandemic (H1N1) 2009-update 103. Available from URL: [accessed June 09, 2010]. http://www.who.int/csr/don/2010_06_04/en/index.html.
2. Central Headquarters for Influenza Control. H1N1 influenza pandemic continues to decline. 2009 H1N1 Flu Press Release, 24 December 2009. Available from URL: [accessed February 01, 2010]. http://www.cdc.go.kr/eng/english/kcdc_01.htm.
3. Korea Centers for Disease Control and Prevention: Surveillance data for week 52, 2009. Influenza Sentinel Surveillance Report 2009; 52. Available from URL: [accessed February 01, 2010]. http://www.cdc.go.kr/eng/english/kcdc_01.htm.
4. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58(RR-8):1-52.
5. Dawood F.S., Jain S., Finelli L., Shaw M.W., Lindstrom S., Garten R.J., et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
6. Centers for Disease Control and Prevention Update: influenza activity, United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep 2010, 59(14):423-430.
7. World Health Organization New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009, 84:249-260.
8. Centers for Disease Control and Prevention. Estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April-December 12, 2009. Available from URL: [accessed January 28, 2010]. http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
9. Neuzil K.M., Dupont W.D., Wright P.F., Edwards K.M. Efficacy of inactivated and cold adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 2001, 20(8):733-740.
10. Ruben F. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004, 38(5):678-688.
11. Ferguson N.M., Cummings D.A.T., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. Strategies for mitigating an influenza pandemic. Nature 2006, 442(7101):448-452.
12. Foy H.M., Cooney M.K., Allan I. Longitudinal studies of types A and B influenza among Seattle schoolchildren and families, 1968-74. J Infect Dis 1976, 134(October (4)):362-369.
13. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. Available from URL: [accessed November 28, 2009]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
14. Concepts and procedures for laboratory based influenza surveillance. Geneva: Viral Disease Unit, World Health Organization, 1982, Available from URL: http://whqlibdoc.who.int/publications/1982/a86910_partA.pdf [accessed January 28, 2010]. A.P. Kendal, M.S. Pereira, J.J. Skehel (Eds.).
15. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103(1-2):133-138.
16. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, March 1997. Available from URL: [accessed January 28, 2010]. http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. Available from URL: [accessed January 28, 2010]. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf.
18. Vaccines and Related Biological Products Advisory Committee, Food and Drug Administration, Center for Biologics Evaluation and Research Office of Vaccines Research and Review. Regulatory considerations regarding the use of novel influenza A (H1N1) virus vaccines. July, 2009. Available from URL: [accessed January 28, 2010]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM172424.pdf.
19. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
20. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
21. National Institute of Allergy and Infectious Diseases. Updated results: In youngest children, a second dose of 2009 H1N1 influenza vaccine elicits robust immune response. November, 2009. Available from URL: [accessed June 9, 2010]. http://www.niaid.nih.gov/news/newsreleases/2009/Pages/interimpedsdata.aspx.
22. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoch M.-K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
23. Parkman P.D., Hopps H.E., Rastogi S.C., Meyer H.M. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977, 136, Suppl:S722-S730.
24. Neuzil K.M., Jackson L.A., Nelson J., Klimov A., Cox N., Bridges C.B., et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006, 194(8):1032-1039.
25. Englund J.A., Walter E.B., Gbadebo A., Monto A.S., Zhu Y., Neuzil K.M. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006, 118(3):e579-e585.
26. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952.
27. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(9708):56-66.
28. Centers for Disease Control and Prevention Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep 2009, 58(39):1100-1101.
29. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
30. Talbot H.K., Keitel W., Cate T.R., Treanor J., Campbell J., Brady R.C., et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008, 26(32):4057-4061.